Cardiol Therapeutics Inc
TSX:CRDL
Cardiol Therapeutics Inc
Free Cash Flow
Cardiol Therapeutics Inc
Free Cash Flow Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Cardiol Therapeutics Inc
TSX:CRDL
|
Free Cash Flow
-CA$25.3m
|
CAGR 3-Years
0%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
N/A
|
|
|
Canopy Growth Corp
TSX:WEED
|
Free Cash Flow
-CA$177m
|
CAGR 3-Years
33%
|
CAGR 5-Years
35%
|
CAGR 10-Years
-49%
|
|
|
Aurora Cannabis Inc
TSX:ACB
|
Free Cash Flow
-CA$28.9m
|
CAGR 3-Years
38%
|
CAGR 5-Years
48%
|
CAGR 10-Years
-10%
|
|
|
Sundial Growers Inc
NASDAQ:SNDL
|
Free Cash Flow
CA$49.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Cronos Group Inc
TSX:CRON
|
Free Cash Flow
-$7.6m
|
CAGR 3-Years
63%
|
CAGR 5-Years
48%
|
CAGR 10-Years
-9%
|
|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
Free Cash Flow
-CA$15.1m
|
CAGR 3-Years
56%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-67%
|
|
Cardiol Therapeutics Inc
Glance View
Cardiol Therapeutics, Inc. is a clinical-stage life sciences company focused on developing anti-inflammatory therapies for cardiovascular disease (CVD). The company is headquartered in Oakville, Ontario and currently employs 11 full-time employees. The company went IPO on 2018-12-20. The firm's lead product, CardiolRx, is a pharmaceutically produced oral cannabidiol formulation that is in a Phase II/III study in hospitalized patients testing positive for COVID-19 with a prior history of, or risk factors for, cardiovascular disease. Cardiol has also received clearance from the Food and Drug Administration (FDA) for its investigational new drug (IND) application for a Phase II international trial that investigates the anti-inflammatory and anti- fibrotic properties of CardiolRx in patients with acute myocarditis, which is a common cause of sudden cardiac death in people under 35 years of age. In addition, Cardiol is developing a subcutaneous formulation of CardiolRx and other anti-inflammatory therapies for the treatment of chronic heart failure.
See Also
What is Cardiol Therapeutics Inc's Free Cash Flow?
Free Cash Flow
-25.3m
CAD
Based on the financial report for Mar 31, 2025, Cardiol Therapeutics Inc's Free Cash Flow amounts to -25.3m CAD.
What is Cardiol Therapeutics Inc's Free Cash Flow growth rate?
Free Cash Flow CAGR 5Y
-20%
Over the last year, the Free Cash Flow growth was -14%.
You don't have any saved screeners yet